BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 11313183)

  • 21. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
    Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
    Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin.
    Kasparkova J; Fojta M; Farrell N; Brabec V
    Nucleic Acids Res; 2004; 32(18):5546-52. PubMed ID: 15486204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.
    Kabolizadeh P; Ryan J; Farrell N
    Biochem Pharmacol; 2007 May; 73(9):1270-9. PubMed ID: 17234160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma.
    Riccardi A; Meco D; Ferlini C; Servidei T; Carelli G; Segni G; Manzotti C; Riccardi R
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):498-504. PubMed ID: 11459202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular pharmacology of polynuclear platinum anti-cancer agents.
    Roberts JD; Peroutka J; Farrell N
    J Inorg Biochem; 1999 Oct; 77(1-2):51-7. PubMed ID: 10626354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin.
    Servidei T; Ferlini C; Riccardi A; Meco D; Scambia G; Segni G; Manzotti C; Riccardi R
    Eur J Cancer; 2001 May; 37(7):930-8. PubMed ID: 11313183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin and platinum drugs at the molecular level. (Review).
    Boulikas T; Vougiouka M
    Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical and molecular mechanisms of cisplatin resistance.
    Siddik ZH
    Cancer Treat Res; 2002; 112():263-84. PubMed ID: 12481720
    [No Abstract]   [Full Text] [Related]  

  • 29. Unusual DNA binding modes for metal anticancer complexes.
    Pizarro AM; Sadler PJ
    Biochimie; 2009 Oct; 91(10):1198-211. PubMed ID: 19344743
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.